Portuguese Consensus Bridging 2023-2025 Hypertension Guidelines for Clinical Practice

5 min read0 viewsJournal Article

GIST

This consensus document, produced by the Portuguese Society of Hypertension and the Portuguese Society of Cardiology, seeks to harmonise partially divergent hypertension guidelines into actionable clinical recommendations for routine practice. It presents a pragmatic synthesis of the 2023 European guidelines and the 2024 ESC guidance, alongside the 2025 AHA/ACC framework, organized according to the M.A.P.E.

(Measure, Assess, Prescribe, Evaluate) framework to support decision-making. The groups emphasize that, across European guidance, hypertension is defined as a blood pressure of at least 140/90 mmHg, with alignment on cardiovascular risk assessment, lifestyle modification, and initial combination therapy using two agents from a common pool.

Divergences exist in classification schemes, initiation thresholds, dosing strategies, and target BP goals; the 2025 AHA/ACC guidelines adopt lower diagnostic and treatment thresholds (≥130/80 mmHg) with earlier pharmacologic intervention based on individual cardiovascular risk. The Portuguese consensus acknowledges these differences and endorses a risk-based approach grounded in randomized trial evidence, prioritizing feasibility and patient safety, and relying on office-based BP measurements for treatment decisions.

Clinical Editorial

Context and purpose

A consensus statement from the Portuguese Society of Hypertension and the Portuguese Society of Cardiology addresses the translation of recent international hypertension guidelines into practical, real-world care.
The document synthesizes and contrasts the 2023 European Society of Hypertension (ESH) guidelines, the 2024 European Society of Cardiology (ESC) guidance, and the 2025 American College of Cardiology/American Heart Association (AHA/ACC) recommendations.
The overarching objective is to reduce clinical uncertainty and support decision-making in routine practice through a pragmatic, evidence-informed framework.

Study design and framework

approach to structure recommendations: Measure, Assess, Prescribe, Evaluate.

The consensus adopts the M.A.P.E.
The synthesis explicitly aims to align divergent guideline elements where feasible while preserving essential differences that arise from varying diagnostic thresholds, risk stratification schemes, and treatment paradigms.
Emphasis is placed on grounding decisions in randomized trial evidence, feasibility in everyday clinical workflows, and patient safety considerations.
The basis for decisions centers on office-based blood pressure measurements as the reference for initiating and guiding therapy in routine care.

Population, exposure, and scope

The document targets adults with hypertension as defined by the integrated sources and focuses on practical application in general clinical practice.
It acknowledges international variations in diagnostic thresholds and treatment targets while proposing a coherent, risk-based decision framework suitable for typical care settings.
The consensus explicitly notes that differences across guidelines pertain to BP classification schemes, initiation thresholds, dosing strategies, and target goals, and it presents reconciled guidance to optimize everyday management.

Key recommendations and comparative signals

Hypertension definition and lifestyle measures: Across European guidelines, hypertension is largely positioned around a threshold of 140/90 mmHg, with aligned recommendations on lifestyle interventions and monitoring, and a common emphasis on initiating combination therapy in appropriate situations.
Initial therapy and drug choices: There is broad agreement on first-line agents and the value of starting with combination treatment in selected patients, though exact thresholds and stepwise approaches vary between European and American guidance.
Thresholds and targets: The ESC/ESH framework and AHA/ACC guidance diverge notably on diagnostic and treatment thresholds, with the latter advocating lower targets (130/80 mmHg) and earlier pharmacologic intervention for higher-risk individuals.
Pragmatic stance: The Portuguese consensus endorses a risk-driven approach that harmonizes evidence from multiple trials, prioritizes practical feasibility, and centers patient safety when applying guideline-based decisions.

Operational implications for clinicians

Decision-making is anchored in clinic-measured blood pressure as the primary driver for treatment choices, with risk stratification informing when to escalate therapy.
Clinicians are encouraged to integrate European and American guideline elements into a cohesive, practical plan that supports routine care without creating excessive complexity.
The document stresses consistency in monitoring, follow-up, and therapy optimization within real-world practice, while acknowledging that some guidelines propose different thresholds and targets.

Limitations and uncertainties

The consensus acknowledges persisting differences among guideline systems, especially regarding BP thresholds, targets, and dosing strategies.
It is explicit that the synthesis is a pragmatic reconciliatory effort, not a replacement for any single guideline, and it bases recommendations on randomized evidence while considering routine feasibility and safety.
Where data or recommendations are ambiguous or not fully aligned, the consensus signals careful, individualized consideration rather than sweeping universal mandates.

Context and relevance to practice

The document positions itself as a bridging resource for clinicians navigating multiple contemporary guidelines, aiming to reduce uncertainty and support everyday care delivery.
By presenting a structured, evidence-informed synthesis, it seeks to facilitate clear, actionable practices in diverse clinical settings while remaining faithful to the source guidelines’ core principles.